Postdoctoral associate earned an American Heart Association fellowship to study how obesity affects pannexin-1 proteins in heart vessels, aiming to uncover new strategies to prevent coronary microvascular dysfunction and obesity-related heart disease.

A team led by University of Virginia School of Medicine researcher James Stone, MD, PhD, has received $3.2 million from the federal Department of Defense to enhance a critical tool for protecting the brain health of military personnel. 

The mammalian liver has an extraordinary regenerative capacity, capable of fully restoring its mass and function after injury or partial resection. A study led by researchers at the University of Barcelona has identified the DNA regions that activate the regeneration of this organ. The study, published in the journal Cell Genomics, provides a genome-wide map of the interactions between these regulatory elements of liver regeneration and the key genes involved in this process. The results provide a better understanding of the fundamental mechanisms of regeneration and could have future implications for the development of regenerative medicine. 

The development of ferroptosis-based nanotherapeutics is generally limited by poor penetration depth into tumors and potential systemic toxicity. 

In a recent issue of International Journal of Extreme Manufacturing, Tu and coworkers from Southern Medical University addressed these challenges by proposing the design and fabrication of self-propelled ferroptosis nanoinducers, composed of only two endogenous proteins with natural bioactivity.

This work offers a strategy for constructing a biocompatible cancer treatment paradigm with enhanced diffusion to achieve deeper penetration into tumor tissues, centered around the concept of ferroptosis.

Organoids, lab-grown 3D miniatures derived from patient tumors, are shedding new light on why some esophageal cancers resist chemotherapy. Researchers at Institute of Science Tokyo (Science Tokyo) used these organoids to pinpoint the molecular drivers of resistance and identified fedratinib as a potential drug. Their findings offer fresh hope for patients with esophageal squamous cell carcinoma, one of the deadliest forms of cancer, by paving the way for more effective, personalized therapies.